Steven Seedhouse
Stock Analyst at Raymond James
(3.27)
# 1,045
Out of 4,734 analysts
162
Total ratings
42.04%
Success rate
3.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $3.28 | +570.73% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $20.00 | +180.00% | 3 | Nov 8, 2024 | |
| ETNB 89bio | Maintains: Strong Buy | $53 → $49 | $6.31 | +676.55% | 10 | Nov 8, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $2.37 | +490.72% | 6 | Oct 29, 2024 | |
| KRRO Korro Bio | Initiates: Strong Buy | $153 | $37.00 | +313.51% | 1 | Oct 21, 2024 | |
| WVE Wave Life Sciences | Upgrades: Strong Buy | $13 → $22 | $10.99 | +100.18% | 2 | Oct 16, 2024 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $116 → $118 | $32.65 | +261.41% | 17 | Jul 25, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $93 | $91.84 | +1.26% | 9 | Jul 8, 2024 | |
| VERA Vera Therapeutics | Maintains: Strong Buy | $57 → $68 | $33.37 | +103.78% | 3 | May 10, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $67 → $106 | $29.94 | +254.10% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.01 | +199.40% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $14.13 | +296.32% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $78 → $64 | $46.95 | +36.32% | 18 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $2.55 | +586.27% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $9.50 | +500.00% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $21 → $19 | $2.54 | +648.03% | 13 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.77 | +1,142.94% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $1.22 | +1,293.44% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $10.31 | +239.48% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $40.61 | -6.43% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $28.92 | +145.50% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.96 | +419.80% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $15.85 | +139.75% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $16.79 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.90 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $140.55 | - | 2 | Apr 23, 2020 |
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $3.28
Upside: +570.73%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $20.00
Upside: +180.00%
89bio
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $6.31
Upside: +676.55%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.37
Upside: +490.72%
Korro Bio
Oct 21, 2024
Initiates: Strong Buy
Price Target: $153
Current: $37.00
Upside: +313.51%
Wave Life Sciences
Oct 16, 2024
Upgrades: Strong Buy
Price Target: $13 → $22
Current: $10.99
Upside: +100.18%
Viking Therapeutics
Jul 25, 2024
Maintains: Strong Buy
Price Target: $116 → $118
Current: $32.65
Upside: +261.41%
Gilead Sciences
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $91.84
Upside: +1.26%
Vera Therapeutics
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $33.37
Upside: +103.78%
Apellis Pharmaceuticals
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $29.94
Upside: +254.10%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.01
Upside: +199.40%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $14.13
Upside: +296.32%
Dec 19, 2023
Maintains: Strong Buy
Price Target: $78 → $64
Current: $46.95
Upside: +36.32%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $2.55
Upside: +586.27%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $9.50
Upside: +500.00%
Nov 2, 2023
Maintains: Strong Buy
Price Target: $21 → $19
Current: $2.54
Upside: +648.03%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.77
Upside: +1,142.94%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $1.22
Upside: +1,293.44%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $10.31
Upside: +239.48%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $40.61
Upside: -6.43%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $28.92
Upside: +145.50%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.96
Upside: +419.80%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $15.85
Upside: +139.75%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $16.79
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.90
Upside: -
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $140.55
Upside: -